Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ОСП «Российский геронтологический научно-клинический центр» – ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, Москва, Россия
Список исп. литературыСкрыть список 1. Симаненков В.И., Маев И.В., Ткачева О.Н. и др. Синдром повышен- ной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваску- лярная терапия и профилактика 2021; 20 (1): 2758. DOI: 10.15829/1728-8800-2021-2758 [Simanenkov V.I., Maev I.V., Tkacheva O.N. et al. Sindrom povyshennoi epitelial'noi pronitsaemosti v klinicheskoi praktike. Mul'tidistsiplinarnyi natsional'nyi konsensus. Kardiovaskuliarnaia terapiia i profilaktika 2021; 20 (1): 2758. DOI: 10.15829/1728-8800-2021-2758 (in Russian).] 2. Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut 2019; 68 (8): 16–1526. DOI: 10.1136/ gutjnl-2019- 31842 3. Sun DC, Shay H. Basal gastric secretion in duodenal ulcer patients: its consideration in evaluation of gastric secretory inhibitants or stimulants. J Appl Physiol 1957; 11 (2): 148–54. DOI: 10.1152/jappl.1957. 11.2.148 4. Оганов Р.Г., Симаненков В.И., Бакулин И.Г. и др. Коморбидная па- тология в клинической практике. Алгоритмы диагностики и лече- ния. Кардиоваскулярная терапия и профилактика 2019; 18 (1): 5– 66. DOI: 10.15829/1728-8800-2019-1-5-66 [Oganov R.G., Simanenkov V.I., Bakulin I. G. et al. Komorbidnaia patologiia v klinicheskoi praktike. Algoritmy diagnostiki i lecheniia. Kardiovaskuliarnaia terapiia i profilaktika 2019; 18 (1): 5–66. DOI: 10.15829/1728-8800-2019-1-5-66 (in Russian).] 5. Fukui H. Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation? Inflamm Intest Dis 2016; 1 (3): 135–145. DOI: 10.1159/000447252 6. Chou RH, Chen CY, Chen IC et al. Trimethylamine N-Oxide, Circulating Endothelial Progenitor Cells, and Endothelial Function in Patients with Stable Angina. Sci Rep 2019; 9 (1): 4249. DOI: 10.1038/s41598-019- 40638-y 7. Kim S, Goel R, Kumar A et al. Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clin Sci (Lond) 2018; 132 (6): 701–18. DOI: 10.1042/CS20180087 8. Rogler G, Rosano G. The heart and the gut. Eur Heart J 2014; 35 (7): 426–30. DOI: 10.1093/eurheartj/eht271 9. Pasini E, Aquilani R, Testa C et al. Pathogenic Gut Flora in Patients With Chronic Heart Failure. JACC Heart Fail 2016; 4 (3): 220–7. DOI: 10.1016/j.jchf.2015.10.009 10. Jin M, Qian Z, Yin J et al. The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med 2019; 23 (4): 2343–50. DOI: 10.1111/ jcmm.14195 11. Воробьева Н.М., Ткачева О.Н. Повышенная проницаемость кишеч- ной стенки и ее роль в возникновении сердечно-сосудистых заболе- ваний. Фарматека 2020; 27 (3): 122–8. DOI: 10.18565/pharmateca. 2020.3.122-128 [Vorobyeva N.M., Tkacheva O.N. Povyshennaia pronitsaemost' kishechnoi stenki i ee rol' v vozniknovenii serdechno-sosudistykh zabolevanii. Farmateka 2020; 27 (3): 122–8. DOI: 10.18565/pharmateca.2020. 3.122-128 (in Russian).] 12. Воробьева Н.М., Ткачева О.Н. Плейотропные эффекты гастроэн- теропротектора ребамипида. Терапия 2020; 6 (4): 142–51. DOI: 10.18565/therapy.2020.4.142-151 [Vorobyeva N.M., Tkacheva O.N. Pleiotropnye effekty gastroenteroprotektora rebamipida. Terapiia 2020; 6 (4): 142–51. DOI: 10.18565/therapy. 2020.4.142-151 (in Russian).] 13. Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические вариан- ты метаболического синдрома. М.: МИА, 2011. ISBN 978-5-9986- 0055-5 [Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. Moscow: MIA, 2011. ISBN 978-5-9986- 0055-5 (in Russian).] 14. Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73 (1): 202–9. DOI: 10.1016/j.jhep. 2020.03.039 15. Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 65 (3): 589–600. DOI: 10.1016/j.jhep.2016.05.013 16. Wu S, Wu F, Ding Y et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. Sci Rep 2016; 6: 33386. DOI: 10.1038/srep33386 17. Zeb I, Li D, Budoff MJ et al. Nonalcoholic Fatty Liver Disease and Incident Cardiac Events: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 2016; 67 (16): 1965–6. DOI: 10.1016/j.jacc.2016.01.070 18. Allen AM, Therneau TM, Larson JJ et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year-community study. Hepatology 2018; 67 (5): 1726–36. DOI: 10.1002/hep. 29546 19. Wong CR, Lim JK. The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. Clin Liver Dis (Hoboken) 2018; 12 (2): 39–44. DOI: 10.1002/cld.721 20. Osawa K, Miyoshi T, Yamauchi K et al. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One 2015; 10 (6): e0131138. DOI: 10.1371/journal.pone.0131138 21. Keskin M, Hayıroglu MI, Uzun AO et al. Effect of Nonalcoholic Fatty Liver Disease on In-Hospital and Long-Term Outcomes in Patients With STSegment Elevation Myocardial Infarction. Am J Cardiol 2017; 120 (10): 1720–6. DOI: 10.1016/j.amjcard.2017.07.107 22. Mantovani A. Nonalcoholic Fatty Liver Disease (NAFLD) and Risk of Cardiac Arrhythmias: A New Aspect of the Liver-heart Axis. J Clin Transl Hepatol 2017; 5 (2): 134–41. DOI: 10.14218/JCTH.2017.00005 23. Mantovani A, Rigamonti A, Bonapace S et al. Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. Diabetes Care 2016; 39 (8): 1416–23. DOI: 10.2337/dc16-0091 24. Targher G, Valbusa F, Bonapace S et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8 (2): e57183. DOI: 10.1371/journal. pone.0057183 25. Karajamaki AJ, Patsi OP, Savolainen M et al. Non-Alcoholic Fatty Liver Disease as a Predictor of Atrial Fibrillation in Middle-Aged Population (OPERA Study). PLoS One 2015; 10 (11): e0142937. DOI: 10.1371/journal. pone.0142937 26. Lazzerini PE, Capecchi PL, Laghi-Pasini F. Long QT Syndrome: An Emerging Role for Inflammation and Immunity. Front Cardiovasc Med 2015; 2: 26. DOI: 10.3389/fcvm.2015.00026 27. Kim HW, Lee DH, Lee SA, Koh G. A relationship between serum potassium concentration and insulin resistance in patients with type 2 diabetes mellitus. Int Urol Nephrol 2015; 47 (6): 991–999. DOI: 10.1007/s11255- 015-1001-5 28. Bonapace S, Valbusa F, Bertolini L et al. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 2014; 9 (2): e88371. DOI: 10.1371/journal. pone.0088371 29. Mantovani A, Pernigo M, Bergamini C et al. Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. Metabolism 2015; 64 (8): 879–87. DOI: 10.1016/j.metabol.2015.04.003 30. Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2018; 15 (7): 425–39. DOI: 10.1038/s41575-018-0010-0 31. VanWagner LB, Wilcox JE, Colangelo LA et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 2015; 62 (3): 773–83. DOI: 10.1002/hep.27869 32. Zhou YY, Zhou XD, Wu SJ et al. Synergistic increase in cardiovascular risk in diabetes mellitus with nonalcoholic fatty liver disease: a metaanalysis. Eur J Gastroenterol Hepatol 2018; 30 (6): 631–6. DOI: 10.1097/MEG.0000000000001075 33. Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7 (4): 313–324. DOI: 10.1016/S2213- 8587(18)30154-2 34. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66 (6): 1138–53. DOI: 10.1136/gutjnl-2017- 313884 35. Hanafi NI, Mohamed AS, Sheikh Abdul Kadir SH, Othman MHD. Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart Biomolecules 2018; 8 (4): 159. DOI: 10.3390/biom8040159 36. Nadinskaia M, Maevskaya M, Ivashkin V et al. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in pa- tients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27 (10): 959–75. DOI: 10.3748/wjg.v27.i10.959 37. Марцевич С.Ю., Кутишенко Н.П., Дроздова Л.Ю. и др. Исследова- ние РАКУРС: повышение эффективности и безопасности терапии статинами у больных с заболеваниями печени, желчного пузыря и/или желчевыводящих путей с помощью урсодеоксихолевой кис- лоты. Терапевтический архив 2014; 12: 48–52. DOI: 10.17116/terarkh2014861248- 52 [Martsevich S.Iu., Kutishenko N.P., Drozdova L.Iu. et al. Issledovanie RAKURS: povyshenie effektivnosti i bezopasnosti terapii statinami u bol'nykh s zabolevaniiami pecheni, zhelchnogo puzyria i/ili zhelchevyvodiashchikh putei s pomoshch'iu ursodeoksikholevoi kisloty. Terapevticheskii arkhiv 2014; 12: 48–52. DOI: 10.17116/terarkh2014861248-52 (in Russian).] 38. Abdel-Wahab BA, Ali FEM, Alkahtani SA et al. Hepatoprotective effect of rebamipide against methotrexate-induced hepatic intoxication: role of Nrf2/GSK-3b, NF-κb -p65/JAK1/STAT3, and PUMA/Bax/Bcl- 2 signaling pathways. Immunopharmacol Immunotoxicol 2020; 42 (5): 493–503. DOI: 10.1080/08923973.2020.1811307 39. Zakaria S, El-Sisi A. Rebamipide retards CCl4-induced hepatic fibrosis in rats: Possible role for PGE2. J Immunotoxicol 2016; 13 (4): 453– 62. DOI: 10.3109/1547691X.2015.1128022 40. Hong KW, Kim KE, Rhim BY et al. Effect of rebamipide on liver damage and increased tumor necrosis factor in a rat model of endotoxin shock. Dig Dis Sci 1998; 43 (9 Suppl.): 154S–159S.